FTC and state enforcement on GLP-1 telehealth: claims, subscriptions, health data
Three enforcement threads matter for GLP-1 telehealth marketing. The FTC's NextMed final order (December 2025) covered unsubstantiated weight-loss claims, fake testimonials, review distortion and undisclosed costs. The FTC, with Utah and California, filed a complaint against Hims & Hers on 29 July 2026 over health-data handling and billing, subscription and cancellation practices. Connecticut's attorney general announced settlements on 6 May 2026 over "generic" and "FDA-approved" framing of compounded GLP-1s and "research grade" sales to consumers.
What each action alleged
NextMed (FTC, 2025): exploiting interest in GLP-1 drugs with unsubstantiated claims about weight loss achieved by clients, fake testimonials, distorted reviews and membership commitments with undisclosed costs; $150,000 for refunds. Hims & Hers (FTC, Utah, California, 2026): as summarised by counsel, misrepresenting how consumer health information was handled, and deceptive billing, subscription and cancellation practices. Connecticut (2025 and 2026): cease-and-desist letters and settlements over advertising compounded GLP-1s as generic or FDA-approved alternatives, and over "research grade" GLP-1 sales to consumers without prescriptions.
Confirmed versus interpretation
Confirmed: the orders, complaints and settlements as published by the FTC and reported by counsel and trade press. Our interpretation: the marketing surfaces named are testimonials and results claims, pricing and subscription pages, comparison framing, and the tracking that moves health information to advertising platforms.
Search and content implications
- Results claims with numbers, and testimonials, are amber at best and need substantiation your counsel accepts.
- Pricing pages that omit membership commitments are a consumer-protection issue and a conversion issue; an honest cost page also outranks aggregators.
- "Generic" and "FDA-approved" framing of compounded products is red.
- Measurement design is compliance: pixel and server events should carry no health information.
Escalation
How these actions apply to your programme is a question for your counsel. This brief records the public record and the marketing surfaces it touches.
Sources
- FTC: FTC approves final order against telehealth provider NextMed (2025-12) — https://www.ftc.gov/news-events/news/press-releases/2025/12/ftc-approves-final-order-against-telehealth-provider-nextmed-over-charges-it-used-deceptive
- Frier Levitt: FTC and states sue Hims & Hers over privacy, billing and subscription practices (2026-07-29) — https://www.frierlevitt.com/articles/ftc-lawsuit-hims-hers-telehealth-privacy-compliance/
- Spakinect: Connecticut Attorney General announces GLP-1 settlements (2026-05-06) — https://www.spakinect.com/news/connecticut-ag-glp1-settlements-med-spa-online-platform
- FTC: Health claims (truth in advertising) — https://www.ftc.gov/news-events/topics/truth-advertising/health-claims
GLP-1SEO provides search-marketing services and publishes search-marketing analysis. We are not physicians, pharmacists, lawyers or regulatory consultants, and nothing on this site is medical, legal or regulatory advice, or advice to patients. Clients remain responsible for obtaining qualified advice about their products, claims, jurisdictions and operations.